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Introduction
 Prostate cancer is one of the most common malignant 
cancers in men and after lung cancer it is the second 
leading cause of mortal cancers in males. The risk of 
prostate cancer for men in their lifetime is 1 in 6 cases, 
which is statistically significant and the high incidence of 
this cancer in middle-aged men is remarkable compared 
to other cancers (Alvarez et al., 2012). According to 
recent studies, 30-50 percent of men over age 50 are 
infected with prostate cancer. Differences in prostate 
cancer incidence and its mortality around the world may 
be related to differences in genetic and environmental 
factors (Ferrís et al., 2011). Recently, the genetic factors 
involved in prostate cancer have been reported and the 
cause of variant of R462Q (rs486907) of the RNASEL 
gene in this cancer has been indicateded. Proteins encoded 
by RNASEL (RNaseL) gene have the effective role in the 
antiviral response induced by interferon Class 1 and 2 for 
human immunity (Casey et al., 2002). 
 The relationship between variants of RNASEL (which 
is a gene with viral activity) with prostate cancer, makes 
this theory that there is likely a viral infection in prostate 
cancer (Chen et al., 2003). To review this issue a Panviral 
Microarray test has been done on patient’s prostate 
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Abstract
 A role for the xenotropic murine leukemia virus (XMRV) in prostate cancer development has been postulated. 
To answer questions regarding the prevalence of XMRV in Iranian patients with prostate cancer and its association 
with the RNASEL R462Q polymorphism, we here investigated a series of cases in Kerman, in the Southeast of 
Iran, and sought to verify the association with the R462Q using Real Time PCR Method. Prostate tissue specimens 
of 200 patients with prostate cancer were genotyped for R462Q by real time polymerase chain reaction allelic 
discrimination and were screened for XMRV proviral DNA by real time polymerase chain reaction specific for 
the envelope gene. Of 200 patients in this study 8 (4%) cases were positive for XMRV, the QQ allele being the 
most frequenct regarding the R426Q polymorphism while in negative patients it was the RQ allele. There was 
significant correlation between high pathological scores and XMRV positive samples. No significant relationship 
was found between age groups and XMRV results. XMRV was only found in patients with QQ and RQ alleles, 
not RR. XMRV is detectable in tumor prostate tissue from some patients with prostate cancer, independent of 
R462Q. 
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tissues who were homozygous individuals for R462Q 
variant. From total 11 samples, 7 patients had a Gama 
retrovirus (Wainberg  et al., 2011). These results indicated 
that there is a significant relationship between RNASEL 
gene malfunction and retroviral infection in the prostate. 
Subsequent reviews to the recognition of this virus showed 
that this is a similar virus with Murine leukemia virus 
(MLV) and therefore it was named xenotropic murine 
leukemia virus - related virus (XMRV) (Urisman et al., 
2006; Robinson et al., 2011). 
 After identification of this virus in prostate cancer 
tissue, different studies on the incidence of this viral 
infection in patients with prostate cancer were done and 
also association of R462Q variant and RNASEL gene 
with the risk of this infection was observed (Arnold et 
al., 2010). The results were different, but in most studies 
the high prevalence of XMRV infection in prostate cancer 
patients than controls has been reported. For the first time, 
(10%) incidence rate of XMRV infection in prostate cancer 
as well as its relationship with mutant R462Q of RNASEL 
gene was reported in 2006 by Urisman and colleagues 
(Urisman et al., 2006). In 2009 a study was conducted 
by Schlaberg and colleagues and the XMRV incidence 
in patients with prostate cancer was reported 27% but 
no association between XMRV infection and mutant 
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R462Q of RNASEL gene was found (Garson et al., 2011). 
In 2010 Arnold and colleagues reported high incidence 
(27.5%) of XMRV infection in prostate cancer patients 
and in similar review study which was done by Urisman 
the mutant R462Q of RNASEL gene was associated with 
XMRV infection (D’Arcy et al., 2008). In 2009, XMRV 
infection was detected in 22RV1 cell line which is derived 
from prostate epithelial cancer cells and also Furuta and 
colleagues reported the 6% incidence of XMRV in prostate 
cancer patients in PBMC samples (Maric et al., 2010). 
Unlike those studies which their results were favor of 
XMRV involvement in prostate cancer, other studies has 
been investigated in which no XMRV infection in prostate 
tissue and prostate cancer patients has been reported. 
 Fortunately, this new virus is sensitive to antiviral 
drugs such as Zidovudine, Tenofovir and Reltegravir 
and with definitive proof about the role of this virus as 
an etiologic factor for prostate cancer; we can reduce 
the risk of this cancer by anti-viral therapy (Sakuma et 
al., 2010). According to the conflicting results about the 
relationship between XMRV and prostate cancer, further 
studies to clarify this issue are required. So the aim of this 
study is the evaluation of XMRV infection incidence, the 
existence of R462Q mutant of RNASEL gene in patients 
with prostate cancer and the association of R462Q mutant 
of RNASEL gene with the risk of XMRV infection which 
was done for the first time in Iran.
 
Materials and Methods
Prostate cancer and tissue preparation
 Paraffin embedded blocks or biopsy samples from 
patients with prostate cancer, referred to the Department 
of Pathology, University Hospital, Kerman Central 
Pathobiology Lab, Kerman province, Iran, and during 
2010-2012 were identified. A total of 460 specimens 
found, but 200 formalin-fixed paraffin-embedded tumor 
tissues of patients collected and entered to our study and 
others patients were lost due to inadequate, absence of 
histological material. No patient had received chemo- or 
radiotherapy before surgery. The present study is based 
on a retrospective examination of prostate carcinoma 
diagnostic biopsy or surgery samples from clinical cases, 
all original hematoxylin and eosin (H&E) slides and/or 
H&E recut from tissue blocks were reviewed. In total, 
200 samples were screened for XMRV and the R462Q 
polymorphism in RNASEL. This project was approved 
by the human research ethics committee of the Kerman 
University of Medical Sciences and participating Centers, 
and written informed consent was obtained from all 
participants. 
Deparaffination samples
 Paraffinated blocks from the 200 tumor samples were 
cut in 5-μm sections and 8 sections/patient were collected 
in the same microcentrifuge tube. Samples were de-waxed 
in 500 μl xylene, All microcentrifuge tube located for 10 
min in a 60 °C heated block and centrifuged at 8,000 rpm, 
supernatant was removed. This step was then repeated 3 
times. Add 500 μl absolute ethanol, centrifuge at 10,000 
rpm for 1 min, the samples were then dried in a 60°C 
heated block with open lids for 10-20 min for remove 
residual ethanol.
Tissue digestion 
 According to samples (biopsy or surgery), 200-400 
μl of Tissue Lysis Buffer was added to each tube [4 
M Urea, 200 mM Tris, 20 mM NaCl, 200 mM EDTA; 
PH=7.4 (25°C)]. To all tubes added 20-40 μl proteinase 
K, Samples were gently vortexes and located for 10 min 
in a 60°C heated block, and all samples were subsequently 
incubated at 37°C overnight.
Provirus DNA Extraction 
 The next day, 200 μl of Binding Buffer [6 M Guanidine-
Hcl, 10mM Urea, 10mM Tris-Hcl, 20% Tritonx-100(v/v); 
PH=4.4(25°C)] was added to each tube with gently vortex. 
DNA was isolated using a QIAamp DNA Mini kit (Qiagen, 
Germany) according to the manufacturer’s instructions. 
Extracted DNA pellets were resuspended in 100μl of 
prewarmed Elution buffer and stored at -20°C until use.
Quality Control 
 The quality and concentration of DNA was measured 
either on an ethidium bromide-stained 1% agarose gel 
or by standard spectrophotometric methods (data not 
shown). Also, presence of DNA and accuracy of DNA 
extraction was confirmed by PCR with human β-globin 
primer as an internal control. The positive control 
consisted of 2 separate reactions, each with DNA isolated 
from XMRV-infected LNCaP cells. The master mix was 
considered to be adequately sensitive only if all 2 positive 
control reactions had positive results. Negative controls 
consisted of 2 separate reactions with H2O in place of DNA 
template and 2 separate reactions of uninfected LNCaP 
DNA. After thermo cycling, second-round reactions were 
electrophoreses on agarose gels containing ethidium 
bromide and were visualized under ultraviolet light. 
Provirus detection 
 A Real Time PCR assay was developed to screen 
prostate tissue DNA for XMRV provirus. The primers 
amplify a 102bp region containing the 3´ variable regions 
of envelope. Primers and probes designed by H.R.Mollaie 
after alignment of complete genomes XMRV consist in 
Nucleotide pubmed database. reactions contained 8µl of 
prostate tissue DNA, 2.5 mmol/L MgCl2, 800 mmol/L of 
dNTPs, 100 ng of each primer, 30 ng of probe and 1.5 units 
of AmpliTaq Gold DNA polymerase (Applied Biosystems) 
in a 50 mL total volume. 
 Thermo cycling conditions were as follows: 95°C 
for 10 min; 40 cycles of 95°C for 15s, 60°C for 40 sec, 
Table 1. Sequence of Primers and Probes and their 
Position with Melting Temperature
Name Sequence Primer and Probes Tm Position
Forward primer GGAAGATGTGGAAAATGA 58.3 266
Reverse primer GGGACTCACCTATTAAGA 58.3 405
R probe ATGAATTTGCCCAAAATGTCCTGTC 67.7 289
Q probe ATGAATTTGCCCGAAATGTCCTGTC 69.2 289
Forward primer CCTGTCTATCTACTACTGTG 59.8 725
Reverse primer GGCCATAAACATAATTAGGG 59.9 826
XMRV probe CCAGAGTTCAACCAGGACACAGTA 69 786
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Table 2. Basic Characteristic of Patients with Prostatic Cancer
Age Group No. Biopsy Embedded Paraffin Extra capsular Seminal Vesicle Surgical Margin XMRV Result
    Block Extension(ECE)  Invasion (SVI) Invasion (SMI)
<40 4 4 0 4 (2%) 0 (0%) 0 (0%) 0 (0%)
  40-50 12 10 2 11 (5.5%) 1 (0.5%) 0 (0%) 1 (0.5%)
  50-60 44 36 8 28 (14%) 8 (4%) 8 (4%) 1 (0.5%)
>60 140 140 0 52 (26%) 22 (11%) 46 (23%) 6 (3%)
Figure 2. Positive Control Samples for XMRV are Positive and Other Positive Samples are Shown but Negative 
Control and Negative Samples are Represented Linearly. About XMRV positive control, because of high titer, our detection 
was done sooner than other positive samples. The specific peak is detected in green channel which identified R allele. On the other 
hand the specific peak is detected in yellow channel which identified presence of Q allele in our samples. 
Figure 1. Frequency. A) Frequency of Gleason Score Age Group, B) Frequency of Gleason Score R426Q Allele. D) Frequency 
of XMRV results for R426Q allele. E) Frequency results of PSA with the combination of XMRV and R426Q (Mean ± SD).
A)                      B)               C)    D)
Quantitative determination of the amplified products 
was done with the Rotor Gene 6000 (Corbett Research, 
Australia). To synthesis of our ideal genes, the test should 
be done by two pairs of forward and reveres primers and 
three different probes to detect allele R, Q and XMRV 
agent. Our specific probes were designed by different 
fluorescent labels for tracking our targets separately. In 
Table 1 the sequences of primers and probes and their 
position with melting temperature are shown.
RNaseL genotyping
 A TaqMan Real-time PCR setup designed by 
H.R.Mollaie, was used for RNaseL genotyping of tumor 
samples which detects the single nucleotide polymorphism 
G1385A (rs486907) responsible for the R462Q mutation 
(Allele change CGA to CAA, R=Arg change to Q=Gln). 
PCR was carried out following a two-step protocol with 
95°C for 10min, 95°C for 15sec and 60°C for 40sec. Data 
acquiring in green channel for R and yellow channel for 
Q polymorphism.
Statistical analysis 
 Chi-square test or Fisher’s exact test was conducted 
using SPSS version 17 for the association between the 
presence of provirus genome and other characterizes 
(values P=0.05 were considered statistically significant).
Results 
 Two hundred patients with prostatic cancer were 
selected during two years (2010-2012). Paraffinated 
blocks or biopsy samples from these patients were selected 
for detection of XMRV and evaluation frequency of 
RNaseL polymorphism using Real Time PCR. Different 
age groups are categorized by less than 40 year old, 40-50, 
50-60 and upper than 60 years. From total 200 samples, 
140 were upper than 60 year which is reported by biopsy 
specimens. According to this individual information, most 
of samples from extra capsular extension (ECE),  seminal 
vesicle invasion (SVI) and surgical margin invasion 
(SMI), were found in patient who were more than 60 years. 
After analysis of data by statistical software (SPSS V-14), 
Pearson correlation of age and PSA was 0.633 and the p 
value=0.000 (see Table 2). 
 In total patients, frequency of R462Q alleles was 
following QQ=45(22.5%), RQ=77(38.5%), RR=78(39%), 
192(96%) of 200 patients was negative results for XMRV 
and 8 samples (4%) was positive for XMRV. In this study 
in patients with positive results, QQ allele 5 patients 
with mean=97.4±70.4 and in RQ allele 3 patients with 
mean=111.7±42.3 are reported and interestingly no XMRV 
gene was detected in RR allele. In patients with negative 
results, QQ allele 40 patients with mean=121.3±54.4 and 
Table 3. Frequency of XMRV Results and R426Q Allele 
Polymorphism in Different Gleason Scores
Gleason 5 6 7 8 9
Negative 19 (9.5%) 26 (13%) 50 (25%) 33 (16.5%) 64 (32%)
Positive 0 (0%) 0 (0%) 2 (1%) 4 (2%) 2 (1%)
R426 Q allele    
 QQ 1 (0.5%) 0 (0%) 17 (8.5%) 11 (5.5%) 16 (8%)
 RQ 4 (2%) 14 (7%) 18 (9%) 18 (9%) 23 (11.5%)
 RR 14 (7%) 12 (6%) 17 (8.5%) 8 (4%) 27 (13.5%)
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in RQ allele 74 patients with mean=104.9±63.4 and also in 
RR allele, 78 patients with mean=85.4±50.5 are reported 
and in all XMRV gene is negative. From total samples, 
the mean of Gleason score in QQ, RQ and RR alleles are 
13.6, 14.2 and 5.8 respectively and no XMRV was found 
in RR allele groups (see Figure 1 and Table 3). Mean of 
Gleason scores in the combination of XMRV results and 
frequency of R426Q alleles are 5.6(QQ), 11.9(RQ) and 
17.7(RR) alleles respectively in cases that are negative 
for XMRV gene. QQ and RQ with the mean=8 and 16 
are shown that are carrying XMRV gene. 
 In Figure 1D three columns are shown which results 
are about Prostatic specific Antigen (PSA) Mean±SD 
with the combination of XMRV and R426Q frequency. 
In QQ and RR homozygous alleles and RQ heterozygote 
allele, XMRV results are shown. From total samples, the 
mean of PSA in QQ, RQ and RR alleles are 16.2, 15.5 
and 7.0 respectively and interestingly the XMRV results 
are positive (green color) in QQ and RQ columns and no 
XMRV was found in RR allele groups (see Figure 2). After 
analysis of data, Pearson correlation of Gleason score and 
PSA was 0.206 and the p value=0.003 were reported. 
Discussion
In 2000, in Italy and Spain, prostate cancer incidence 
was ranked third (approximately 10%), while in France 
it was the most common male cancer (approximately 
19%) (Quaglia et al., 2003).Some previous studies have 
reported that opposite of Europe and America, prostate 
carcinoma is not common in Iran. It has been estimated 
that the incidence of prostate cancer has increased in 
Iranian immigrants to Western countries (Hosseini et 
al., 2010). Although current data on the epidemiology 
of prostate cancer in Iran are vague and incomplete, this 
cancer is the eighth leading cause of death from cancer 
in Iran and the incidence of this cancer has been rising 
in the last 10 years in Iran. It is thought that 42 percent 
of prostate cancer cases due to genetic factors and 58 
percent are because of environmental factors but various 
causes of prostate cancer is still not well known even in 
some cases  different results have been seen in this field. 
Prostate specific antigen (PSA) testing for prostate cancer 
screening can signal the presence of impalpable and thus 
previously undetectable cancer. Consequently, intensified 
effort in early detection of prostate cancer through PSA 
screening has amplified the incidence of prostate cancer 
by allowing the detection of localized latent cancer 
lesions, whereas in our country, data on incidence of 
prostate cancer only reflect the clinically obvious diseases 
(Sadjadi et al., 2007). In 2002, Carpten et al. proposed 
RNASEL as an effective gene for prostate cancer. To 
test this hypothesis that RNASEL sequence variants are 
associated with prostate cancer, we studied SNPs variants 
R462Q and 200 prostate cancer patients. Overall, our 
study provided support for the hypothesis that RNASEL 
is a prostate cancer susceptibility gene and suggestive 
evidence of relation between mutations (RR, RQ, and 
QQ) and prostate cancer was observed and we observed 
identical frequencies of R462Q mutation carriers among 
sporadic prostate cancer cases (Summers et al., 2008). The 
common missense mutation R462Q has been studied in 
prostate cancer risk, using 423 prostate cancer cases and 
454 sibling controls, Casey et al. showed that heterozygous 
carriers of this variant have 50% greater risk of prostate 
cancer than no carriers, and homozygous carriers have 
more than double the risk (Casey et al., 2002). They also 
reported a decrease in enzymatic activity of the variant 
to one-third of normal activity. Rökman et al. reported 
moderate evidence for an increased risk of prostate cancer 
for homozygous carriers of the R462Q variant in 66 index 
patients from HPC families (Rökman et al., 2001). In 
addition, Nakazato et al. reported an association between 
this variant and prostate cancer risk among 473 affected 
men from 181 families; however, they found an opposite 
trend with odds ratios of 0.8 for heterozygotes and 0.5 
for homozygotes (Nakazato et al., 2003). This missense 
variant was significantly associated with an increased 
prostate cancer risk in a study from Japan based on 101 
familial prostate cancer cases and 105 controls, yet other 
studies have failed to find an association between this 
variant and prostate cancer risk (Nakazato et al., 2003). 
In conclusion, we confirm the involvement of RNASEL 
in the prostate cancer and we provide some evidence for 
an association of the RNASEL gene with prostate cancer 
in Iranian men. The prostate cancer risk is varied between 
racial/ethnic groups, indicating that race/ethnicity plays 
a role in the development of prostate cancer. This is 
because each case brings genetic material that sets each 
race and ethnicity apart and also the combination between 
environmental factors and genetic background can play 
a role in this cancer(Huihua et al., 2006). Our study of 
patients with prostate cancer confirms the presence of 
XMRV among patients with prostate cancer in the Iran. 
The results presented here identify XMRV infection in 
prostate tissue from patients with prostate cancer as judged 
by Real time-PCR with XMRV-specific primers. It clearly 
demonstrated that human XMRV infection is strongly 
linked to RNase L activity. This result supports the view 
that the R462Q RNase L variant leads to a subtle defect 
in innate (IFN-dependent) antiviral immunity. 
Interestingly, some studies, including 2 surveys of 
German prostate tissue specimens and a screen of English 
chronic fatigue syndrome patients, found no evidence 
of XMRV infection (Hong et al., 2012). However, in 
agreement with studies performed in the United States, 
they found the presence of XMRV in prostate cancer 
tissues (Bjartell, 2006). It is possible that XMRV is 
mostly present in the Iranian population. If so, it would 
be interesting to know the reason for this geographic 
distribution. Alternatively, the inability to detect XMRV 
in the world may possibly reflect genetic differences 
between different strains. However, this seems unlikely 
considering the high degree of sequence conservation 
among XMRV isolates and the variety of primer target 
sequences used for detection among the studies in Europe 
(Klein and Silverman, 2010). It is possible that the quality 
of the specimens were low because of preservation, 
handling, and the duration of storage prior to DNA 
isolation. However, we were able to detect the patients for 
R462Q with use DNA without difficulty. We did not find a 
correlation between XMRV infection and various clinical 
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pathological parameters of prostate cancer, including 
seminal vesicle invasion, extra capsular extension, and 
surgical margin invasion. From total samples, the mean 
of Gleason score in QQ, RQ and RR alleles are 13.6, 
14.2 and 5.8 respectively and no XMRV was found in 
RR allele groups.  Similar to another report, which found 
a correlation with higher Gleason scores, we found a 
slight trend in favor of increasing Gleason score (Trottier 
and Fleshner, 2010) . In conclusion, our study supports a 
hypothesis that XMRV is endemic to Middle East and Iran. 
However, more investigation into the relation of XMRV 
with prostate cancer and other human diseases is needed. 
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